FinTrust Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

FinTrust Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$8.46K	Hold	180	–	–	﹤0.01%	977
2024 Q2	$9.72K	Hold	180	–	–	﹤0.01%	907
2024 Q1	$12.3K	Hold	180	–	–	﹤0.01%	823
2023 Q4	$11.3K	Hold	180	–	–	﹤0.01%	810
2023 Q3	$8.17K	Sell	180 -377	-68%	-$19.5K	﹤0.01%	814
2023 Q2	$22.6K	Hold	557	–	–	0.01%	621
2023 Q1	$22.6K	Hold	557	–	–	0.01%	619
2022 Q4	$22.6K	Hold	557	–	–	0.01%	618
2022 Q3	$32K	Sell	557 -402	-42%	-$29.1K	0.01%	604
2022 Q2	$73K	Hold	959	–	–	0.02%	460
2022 Q1	$60K	Sell	959 -26,984	-97%	-$1.69M	0.01%	524
2021 Q4	$2.12M	Buy	27,943 +2,161	+8%	+$189K	0.51%	47
2021 Q3	$2.89M	Sell	25,782 -210	-0.8%	-$26.4K	0.76%	29
2021 Q2	$4.21M	Buy	25,992 +1,159	+5%	+$141K	1.1%	15
2021 Q1	$3.03M	Sell	24,833 -396	-2%	-$59.8K	0.87%	21
2020 Q4	$3.86M	Buy	25,229 +801	+3%	+$94.7K	1.23%	12
2020 Q3	$2.04K	Sell	24,428 -1,721	-7%	-$153K	0.4%	36
2020 Q2	$1.92M	Buy	26,149 +25,014	+2,204%	+$1.46M	0.76%	34
2020 Q1	$48K	Sell	1,135 -100	-8%	-$5.16K	0.02%	442
2019 Q4	$75K	Hold	1,235	–	–	0.03%	368
2019 Q3	$51K	Buy	+1,235	New	+$59K	0.02%	444

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FinTrust Capital Advisors's CRSP Position: Q3 2024 in Review

FinTrust Capital Advisors held its CRISPR Therapeutics (CRSP) position steady in Q3 2024 at 180 shares worth $8.46K. The position accounts for ﹤0.01% of the portfolio, ranked #977.

FinTrust Capital Advisors first reported a position in CRSP in Q3 2019 and has held it in 21 quarters since. The position peaked at $4.21M in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

FinTrust Capital Advisors held 180 shares of CRISPR Therapeutics worth $8.46K as of Q3 2024.
FinTrust Capital Advisors left its CRISPR Therapeutics share count unchanged in Q3 2024.
CRISPR Therapeutics made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #977 holding.
FinTrust Capital Advisors first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 21 quarters since.
FinTrust Capital Advisors's CRISPR Therapeutics position peaked at $4.21M in Q2 2021.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.